The shadow of generic rivalry has consistently loomed over copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the outlook of similar pharmaceutical stakes. While early periods saw significant profits, the intellectual property lapse has created the door for less expensive alternatives, potentially lowering earnings and prese